Fulcrum Therapeutics Inc Q2 2026 Earnings: Beat on EPS

Fulcrum Therapeutics Inc (FULC) reported second-quarter 2026 earnings that exceeded analyst expectations, posting a loss of $0.25 per share compared to the consensus estimate of $0.30 per share loss.

The biotechnology company delivered an earnings surprise of 17.79%, beating Wall Street forecasts by $0.05 per share. The actual EPS of -$0.25 represented a smaller loss than the -$0.30 that analysts had projected for the quarter ended in Q2 2026.

FULC announced these results on April 27, 2026, marking another quarter where the company’s financial performance surpassed analyst expectations by nearly 18%. The $0.05 per share beat demonstrates the company’s ability to manage expenses more effectively than anticipated.

Revenue figures were not disclosed in the earnings report for the second quarter of 2026. The earnings beat of 17.79% suggests improved operational efficiency compared to analyst models that had predicted a $0.30 per share loss.

This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.